Kandonga Daniel, Sangeda Raphael Zozimus, Masamu Upendo, Kazumali Eliah, Jonathan Agnes, Msangawale Michael, Kaihula Winfrida, Rwegalulila Julieth, Ondego Jesca, Tutuba Hilda J, Ndunguru Joyce, Ambrose Emmanuela E, Kidenya Benson R, Yonazi Mbonea, Kyomugisha Irene, Mupfururirwa Wilson, Jonas Mario, Nembaware Victoria, Mazandu Gaston Kuzamunu, Kengne Andre Pascal, Wonkam Ambroise, Makani Julie, Balandya Emmanuel
Sickle Cell Programme, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Department of Pharmaceutical Microbiology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Front Hematol. 2023;2. doi: 10.3389/frhem.2023.1040720. Epub 2023 Apr 10.
Sickle cell disease (SCD) is a severe hereditary form of anemia that contributes between 50% and 80% of under-five mortality in Africa. Eleven thousand babies are born with SCD annually in Tanzania, ranking 4 after Nigeria, the Democratic Republic of Congo and India. The absence of well-described SCD cohorts is a major barrier to health research in SCD in Africa.
This paper describes the Sickle Pan African Consortium (SPARCO) database in Tanzania, from the development, design of the study instruments, data collection, analysis of data and management of data quality issues.
The SPARCO registry used existing Muhimbili Sickle Cell Cohort (MSC) study case report forms (CRF) and later harmonized data elements from the SickleInAfrica consortium to develop Research Electronic Data Capture (REDCap) instruments. Patients were enrolled through various strategies, including mass screening following media sensitization and health education events during World Sickle Cell Day each June and the SCD awareness month in September. Additional patients were identified through active surveillance of previously participating patients in the MSC.
Three thousand eight hundred patients were enrolled between October 2017 and May 2021. Of these, 1,946 (51.21%) were males and 1,864 (48.79%) were females. The hemoglobin phenotype distribution was 3,762 (99%) HbSS, 3 (0.08%) HbSC and 35 (0.92%) HbSb +thalassemia. Hemoglobin levels, admission history, blood transfusion and painful events were recorded from December 2017 to May 2021.
The Tanzania SPARCO registry will improve healthcare for SCD in Africa through the facilitation of collaborative data-driven research for SCD.
镰状细胞病(SCD)是一种严重的遗传性贫血,在非洲5岁以下儿童死亡率中占50%至80%。坦桑尼亚每年有1.1万名婴儿患有镰状细胞病,在尼日利亚、刚果民主共和国和印度之后排名第四。缺乏详细描述的镰状细胞病队列是非洲镰状细胞病健康研究的主要障碍。
本文描述了坦桑尼亚的镰状细胞病泛非联盟(SPARCO)数据库,包括其开发、研究工具设计、数据收集、数据分析以及数据质量问题管理。
SPARCO登记处使用了现有的穆希姆比利镰状细胞病队列(MSC)研究病例报告表(CRF),随后整合了来自非洲镰状细胞病联盟的数据元素,以开发研究电子数据采集(REDCap)工具。通过多种策略招募患者,包括在每年6月世界镰状细胞病日以及9月镰状细胞病宣传月开展媒体宣传和健康教育活动后进行大规模筛查。通过对MSC中先前参与研究的患者进行主动监测,识别出更多患者。
2017年10月至2021年5月期间共招募了3800名患者。其中,男性1946名(51.21%),女性1864名(48.79%)。血红蛋白表型分布为:HbSS型3762例(99%),HbSC型3例(0.08%),HbSb+地中海贫血型35例(0.92%)。记录了2017年12月至2021年5月期间的血红蛋白水平、入院史、输血情况和疼痛事件。
坦桑尼亚的SPARCO登记处将通过促进基于数据的镰状细胞病协作研究,改善非洲镰状细胞病的医疗保健。